From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia
- 16 June 2011
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 117 (24), 6425-6437
- https://doi.org/10.1182/blood-2010-11-283598
Abstract
Arsenic had been used in treating malignancies from the 18th to mid-20th century. In the past 3 decades, arsenic was revived and shown to be able to induce complete remission and to achieve, when combined with all-trans retinoic acid and chemotherapy, a 5-year overall survival of 90% in patients with acute promyelocytic leukemia driven by the t(15;17) translocation-generated promyelocytic leukemia–retinoic acid receptor α (PML-RARα) fusion. Molecularly, arsenic binds thiol residues and induces the formation of reactive oxygen species, thus affecting numerous signaling pathways. Interestingly, arsenic directly binds the C3HC4 zinc finger motif in the RBCC domain of PML and PML-RARα, induces their homodimerization and multimerization, and enhances their interaction with the SUMO E2 conjugase Ubc9, facilitating subsequent sumoylation/ubiquitination and proteasomal degradation. Arsenic-caused intermolecular disulfide formation in PML also contributes to PML-multimerization. All-trans retinoic acid, which targets PML-RARα for degradation through its RARα moiety, synergizes with arsenic in eliminating leukemia-initiating cells. Arsenic perturbs a number of proteins involved in other hematologic malignancies, including chronic myeloid leukemia and adult T-cell leukemia/lymphoma, whereby it may bring new therapeutic benefits. The successful revival of arsenic in acute promyelocytic leukemia, together with modern mechanistic studies, has thus allowed a new paradigm to emerge in translational medicine.Keywords
This publication has 183 references indexed in Scilit:
- Arsenic trioxide — An old drug rediscoveredBlood Reviews, 2010
- Changing nuclear landscape and unique PML structures during early epigenetic transitions of human embryonic stem cellsJournal of Cellular Biochemistry, 2009
- A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemiaProceedings of the National Academy of Sciences, 2009
- Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyHematological Oncology, 2008
- PML targeting eradicates quiescent leukaemia-initiating cellsNature, 2008
- Dissection of mechanisms of Chinese medicinal formula Realgar- Indigo naturalis as an effective treatment for promyelocytic leukemiaProceedings of the National Academy of Sciences, 2008
- Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxideProceedings of the National Academy of Sciences, 2007
- Identification of arsenic-binding proteins in human breast cancer cellsCancer Letters, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Dynamics of chronic myeloid leukaemiaNature, 2005